
The Rate of Ward to Intensive Care Transfer and Its Predictors Among Hospitalized COPD Patients, a Retrospective Study in a Local Tertiary Center in Saudi Arabia

Abdallah Y Naser^{1*†}, Mohammad Saleh Dairi^{2†}, Hassan Alwafi^{2*}, Deema Sami Qadus³, Abdulelah M Aldhahir⁴, Abdullah A Alqarni⁵, Wael Aly Elrefaey⁶, Sultan Qanash⁷, Waleed Hafiz², Jaber S. Alqahtani⁸, Rakan Ekram⁹, Amjad Abuirmeileh¹⁰, Anan S. Jarab^{11,12,13} and Omaima Ibrahim Badr^{6,14}



Introduction

- > Recent advances in clinical and translational research have confirmed chronic obstructive pulmonary disease (COPD) complex phenotyping as well as its associated extra-pulmonary consequences¹. Comorbidities coexisting with COPD imply a more severe course of the disease, with more frequent exacerbations and hospitalizations¹⁻³. People who have two or more exacerbations per year have a lower quality of life, a faster loss of lung function, more hospitalizations, and a higher mortality rate⁴⁻⁷.
- \triangleright A previous study conducted in Saudi Arabia assessed the outcomes of patients hospitalized with exacerbation of COPD within the hospital setting, specifically focusing on in-hospital and intensive care unit (ICU) outcomes⁸. However, the predictors and prevalence of ICU admission in hospitalized COPD patients have not been well elucidated in prior studies in the region.

Objectives: To investigate the prevalence of ICU admission and its predictors among hospitalized COPD patients.

Affiliations

¹Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan. ²Pharmacology and Toxicology Department, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia. ³Department of Pharmacy, Faculty of health sciences, American University of Madaba, Madaba, Jordan. ⁴Respiratory Therapy Department, Faculty of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia. ⁵Department of Respiratory Therapy, Faculty of Medical Rehabilitation Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. ⁶Department of Pulmonary Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia. ⁷Department of Internal Medicine, National Guard Hospital, Jeddah, Saudi Arabia. ⁸Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia. ⁹School of Public Health Informatics, Umm Al-Qura University, Mecca, Saudi Arabia. ¹⁰Faculty of Pharmacy, Middle East University, Amman, Jordan. ¹¹College of Pharmacy, AL Ain University, P.O. Box 112612, Abu Dhabi, United Arab Emirates. ¹²AAU Health and Biomedical Research Center, Al Ain University, P.O. Box 112612, Abu Dhabi, United Arab Emirates. ¹³Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan. ¹⁴Department of Chest Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.

Methods and Materials

- An observational retrospective study was conducted.
- All patients with a confirmed diagnosis of COPD according to the GOLD guidelines between 28 February 2020 and 1 March 2023 at Al-Noor Specialist Hospital were included in this study. Patients were excluded if a preemptive diagnosis of COPD was made clinically without spirometry evidence of fixed airflow limitation.
- [⊥] Descriptive results were presented as frequency (percentage) for categorical variables and mean (SD) for continuous variables to estimate the prevalence of ICU admission. Predictors of ICU admission among hospitalized COPD patients were determined using logistic regression analysis.
- to perform all statistical analysis.

Results

 \succ A total of 705 patients with COPD were included in this study.

The mean age was 65.4 (25.3) years. Around 12.4% of the hospitalized patients were admitted to the ICD.

 \succ Logistic regression analysis identified that older age (OR; 1.92, (1.41– 2.62)), smoking (OR; 1.60 (1.17–2.19)), and having specific comorbidities (Hypertension (OR; 1.98 (1.45–2.71)), Diabetes mellitus (OR; 1.42 (1.04– 1.93)), GERD (OR; 2.81 (1.99–3.96)), Ischemic heart disease (OR; 3.22 (2.19– 4.75)), Obstructive sleep apnea syndrome (OR; 2.14 (1.38–3.33)), stroke (OR; 4.51 (2.20–9.26))) were predictors of ICU admissions among patients with COPD.

Table 1 Medications use history
 Variable Frequency 640 SABA LAMA 567 LABA 418 ICS 390 139 Systematic

corticosteroids 55 Home oxygen and BIPAP 37

Home oxygen

References

Percentage
90.80%
80.40%
59.30%
55.30%
19.70%
7.80%
5.20%

N / P I I	Odds ratio (95% confidence	
Variable	interval)	p-value
	Gender	
emales (Reference group)	1.00	
Males	1.05 (0.77–1.43)	0.770
	Mean age	
Below 65 years old	1.00	
65 years and over	1.92 (1.41–2.62)	≤ 0.001
_	Mean Body Mass Index (BMI)	
Below 29.2 kg/cm ²	1.00	
29.2 kg/cm ² and over	1.12 (0.82–1.52)	0.489
	Smoking status	
Non-smoker (Reference	1.00	
group)	T.00	
Ex-smoker	0.57 (0.41–0.78)	≤ 0.001
Current smoker	1.60 (1.17–2.19)	0.003
	Receive home care	
No (Reference group)	1.00	
Yes	6.32 (3.32–12.01)	≤ 0.001
	Comorbidities	
Hypertension	1.98 (1.45–2.71)	≤ 0.001
Diabetes mellitus	1.42 (1.04–1.93)	0.027
Gastroesophageal disease (GERD)	2.81 (1.99–3.96)	≤ 0.001
Ischemic heart disease	3.22 (2.19–4.75)	≤ 0.001
Obstructive sleep apnoea syndrome	2.14 (1.38–3.33)	≤ 0.001
Heart failure	5.16 (2.93–9.10)	≤ 0.001
Chronic kidney disease	1.75 (0.92–3.31)	0.087
stroke	4.51 (2.20–9.26)	≤ 0.001
Connective tissue diseases	0.46 (0.17–1.25)	0.128
Tumour or malignancy	3.12 (1.03–9.40)	0.044
Hemiplegia	2.22 (0.82–6.02)	0.119
Peripheral vascular diseases	0.63 (0.17–2.40)	0.498

Our study found that a step-up approach to inpatient COPD management requires admission to the ICU in 12.4%, for which age, smoking status, cardiovascular, and stroke were important predictors. Further clinical research is needed to provide a validated model that can be incorporated into clinical practice to monitor this patient population during admission and identify at-risk individuals for early transfer to higher acuity settings and ICUs.

1. Chick DA, Van Harrison GP et al. R, Chronic Obstructive Pulmonary Disease. 2020; Available from: https://www.ncbi.nlm.nih.gov/books/NBK568512/. 2. Decramer M, Janssens W, Miravitlles M. Chronic Obstructive Pulmonary Disease. The Lancet. 2012;379(9823):1341–51.

3. Mannino DM, et al. Prevalence and outcomes of Diabetes, Hypertension and Cardiovascular Disease in COPD. Eur Respir J. 2008;32(4):962–9.

4. Doll H, Miravitlles M. Health-related QOL in acute exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease: a review of the literature. PharmacoEconomics. 2005:23:345-63.

5. Soler-Cataluña J, et al. Severe acute exacerbations and mortality in patients with Chronic Obstructive Pulmonary Disease. Thorax. 2005;60(11):925–31. 6. Beeh KM, et al. Characterisation of exacerbation risk and exacerbator phenotypes 2012;7:819–23. in the POET-COPD trial. Respir Res. 2013;14(1):1–8.



Conclusions

7. Hurst J. Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators: susceptibility to exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010;363:1128–38. 8. Alaithan AM, et al. Chronic Obstructive Pulmonary Disease: hospital and intensive care unit outcomes in the Kingdom of Saudi Arabia. Int J Chron Obstruct Pulmon Dis.